Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-715-3 | CAS number: 55589-62-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 25
- Absorption rate - inhalation (%):
- 100
Additional information
Acesulfame potassium has been evaluated thoroughly in a series of studies designed to establish its safety as a sweetener for food use. The database on covers chemistry, physiology, metabolism, pharmacology, pharmacokinetics and toxicology with data generated in a wide variety of in vivo and in vitro test systems including several animal species and humans.
Kinetics and biotransformation of Acesulfame potassium were studied in animal species and in humans. In none of the studies on biotransformation which were performed with radiolabelled material formation of metabolites was detected. Within the normal recovery rates of this type of study all activity was recovered as the unmetabolised Acesulfame and no other compounds showing activity were found.
The specific endpoint of the kinetic studies was the determination of maximum blood and serum levels and elimination rates but not the investigation of internal doses. Absorption and elimination were fast in rats, dogs, and man.
The most recent and valid study was performed in two groups of 48 male and 48 female Wistar rats each received dietary concentrations of 9000 and 15000 ppm for two weeks. The corresponding intake in mg/kg body weight was calculated on the basis of feed consumption and body weight as
9000 ppm males: 854.68 mg/kg bw/d
females: 827.39 mg/kg bw/d
15000 ppm males: 1367.07 mg/kg bw/d
females: 1277.22 mg/kg bw/d
No abnormalities and no intercurrent deaths occurred during the study.
The blood of one male and one female animal at each time point was collected over a period of 24 h at 0.5 h intervals by exsanguination on day 14 and 15 of the study. The levels of Acesulfame potassium in serum were thus determined over the last 24 h of the study.
The following AUC(24h) values were obtained:
9000 ppm males: 848.2 µg.h/ml
females: 933.5 µg.h/ml
15000 ppm males: 1520.6 µg.h/ml
Females: 1671.1 µg.h/ml
No remarkable sex differences were observed with Acesulfame potassium. The levels of Acesulfame potassium and consequently also the AUC(24h) values were about 10 % higher in females than in males_ The increase in the AUC(24h) of Acesulfame potassium was virtually proportional to the given dose. The 17 fold increase in the dose resulted in an 1.8 fold increase in the AUC(24h).
To compare the kinetics in dogs with the kinetics observed in rats a study using two groups of three male and three female beagle dogs each was carried out. Acesulfame potassium was administered orally in the daily diet at concentrations of 900 and 1500 mg/kg bw/d over a period of 14 days. The levels of Acesulfame potassium in serum were determined after the first and the 14th administration. Blood sampling was performed before and 0.5, 1, 1.5, 2, 3, 5, 7, 12, 20, and 24 h after administration.
No abnormalities were observed in the course of the study, and all dogs survived until the scheduled end of the study. While food consumption was normal in the lower dosage group, some animals of the high dosage group showed retarded food consumption.
The AUC(24h) ranged from 2149 to 3819 µg.h/ml in the 900 mg/kg bw/d group and from 3065 to 5722 µg.h/ml in the 1500 mg/kg bw/d group.
Peak concentrations of the level (Cm) of Acesulfame potassium were reached 5 to 7 h after dosing with maximum concentrations of 180 to 311 µg/ml at the 900 mg/kg bw/d dose and 273 to 491 µg/ml at 1500 mg/kg bw/d
The plasma half-lives (t1/2) ranged from 2.3 to 4.2 h with a median of 3.2 h.
The increase of Cmax. and AUC(24h) was virtually proportional to the dose given. The 1.7 fold increase in the dose was followed by a 1.6 to 1.9 fold increase in maximum concentrations and a 1.5 to 1.8 fold increase in AUC(24h) values.
No remarkable sex-specific differences were seen. Accumulation can be excluded on the basis of values obtained after the 14th administration, as the Cmax were 0.9 to 1.4 fold and the AUC(24h) 0.9 to 1.2 fold the first administration.
Results of the kinetic studies in rats and dogs show that the same dosage of Acesulfame potassium expressed as mg/kg body weight results in substantially higher internal doses in dogs than in rats. For 900 mg/kg the internal doses determined by AUC(24h) values are 2.3 — 4.5 fold higher in dogs than in rats and for 1500 mg/kg bw/d 1.8 — 2.7 fold higher. Even a comparison of the AUC(24h) value determined for dogs at the 900 mg/kg bw/d dosage level exceeds the AUC(24h) value for rats at the 1500 mg/kg level by a factor of 1.3 — 2.5.
Only steady state and not peak plasma concentration (Cmax) values, could be obtained for rats since administration was by
continuous feeding. The increases in AUC(24h) in both species and in Cmax in the dog were virtually proportional to dose
Comparative toxicokinetics of Acesulfame potassium in rats and dogs Comparative toxicokinetics of Acesulfame potassium in rats and dogs.
|
AUC(24h) (ìg.h.ml-1) |
Plasma concentration (ìg.ml-1) |
||
Species |
Rat |
Dog |
Rat steady state |
Dog Cmax |
Lower dose 1) |
848-934 |
2149-3819 |
16-71 |
180-311 |
Higher dose 2) |
1521-1671 |
3065-5722 |
30-119 |
273-491 |
1) Rat: 840 mg/kg bw/day via diet; dog: 900 mg/kg bw/day as bolus dose 2) Rat: 1325 mg/kg bw/day via diet; dog: 1500 mg/kg bw/day as bolus dose
|
Metabolism studies
Single oral doses of Acesulfame potassium given to dogs and rats were rapidly absorbed and excreted mainly in the urine as unchanged compound.
The excretion kinetics of Acesulfame potassium in the rat is biphasic with an estimated half-life in the rapid phase of approximately 4 hrs.
When single doses of Acesulfame potassium were given orally to dogs and pigs, maximum blood levels were reached at 1-2 hrs after dosing.
A single oral dose of 30 mg Acesulfame potassium given to human volunteers was rapidly and almost completely absorbed.
In human maximum blood concentration was reached after 1- 1.5 h and thereafter elimination occurred rapidly with a plasma half-life of 2-2.5 h. Only the parent compound could be identified in serum and urine, indicating that no significant degradation of Acesulfame potassium had occurred.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.